ACHIEVE LIFE SCIENCES, INC.
ACHV · XNASCIK 949858fmd_01SPE47R2V4BQSZDFWRHHHGTE9Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | – | – | – | – | – | – |
| Research and development | 0 | 3 | 6 | 10 | 7 | 24 | 30 | 16 | 23 | – |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Interest expense | – | – | – | – | – | – | 2 | 3 | 2 | 1 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 |
| Other non-operating income (expense) | (0) | (7) | 0 | 0 | 0 | (0) | (2) | (3) | (1) | 0 |
| Income before taxes | (2) | (14) | (13) | (16) | (15) | (33) | (42) | (30) | (40) | (55) |
| Income tax expense | 0 | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | (2) | – | – | – | – | – | – | – | – | – |
| Net income | (1) | (11) | (13) | (16) | (15) | (33) | (42) | (30) | (40) | (55) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |